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Abstract The cDNA encoding bovine lactoperoxidase (LPO)
has been expressed in CHO cells. The recombinant LPO was
secreted as an enzymatically active single chain molecule
presenting two immunoreactive forms of 88 kDa and 82 kDa,
differing by their glycosylation. rLPO exhibited the character-
istic absorbance spectrum with a Soret peak at 413 nm.
Engineering of rLPO into a myeloperoxidase (MPO)-like
molecule was attempted by substituting Gln-376 by Met, a
residue known to achieve covalent binding with the heme in
MPO. However, the resulting bovine LPO mutant failed to
acquire the peculiar absorbance spectrum and the chlorinating
activity of MPO, underlining the complex nature of interactions
in the heme vicinity.
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1. Introduction
Lactoperoxidase (LPO) is a heme-containing enzyme
present in milk, saliva and tears and is part of an antimicro-
bial defense system, converting thiocyanate to hypothiocyan-
ite in an H2O2-dependent reaction. The molecular weight of
LPO is approximately 80 kDa and its carbohydrate moiety
represents about 10% of the total weight [1,2].
LPO, myeloperoxidase (MPO), eosinophil peroxidase
(EPO) and thyroid peroxidase (TPO) belong to the homolo-
gous mammalian peroxidase family and share 50^70% iden-
tity. An even higher homology can be found among the active
site-related residues. These peroxidases have the ability to
catalyze the oxidation of halides and pseudohalides such as
thiocyanate by hydrogen peroxide to form potent oxidant and
bactericidal agents. As the heme is intimately associated with
the enzymatic activity, its structure and linkage with neighbor-
ing amino acids have been studied in terms of spectral analysis
in LPO, EPO and MPO [3^5]. Recently, direct spectroscopic
evidence has been given for the presence of two ester linkages
between the heme and the protein carbonyl groups in these
mammalian peroxidases [5].
MPO is the only member of the family for which the X-ray-
derived structure has been described [6,7] ; for bovine LPO
[8,9], human EPO [10,11] and TPO [12], only primary sequen-
ces are known. Based on the MPO X-ray structure, a theo-
retical model for LPO and EPO has been built, showing evi-
dence supporting the hypothesis of ester linkages between the
heme and the apoproteins [13]. The structure and heme bind-
ing in MPO have been elucidated and are consistent with a
protoporphyrin-IX derivative, linked to the polypeptide chain
by two ester linkages with glutamic and aspartic side chains of
the residues Glu-408 and Asp-260. An additional covalent
sulfonium linkage with the methionine 409 of the MPO poly-
peptide chain has also been shown [6,7,14,15]. This third co-
valent linkage with Met-409 is responsible for the peculiar
spectroscopic feature of MPO, namely the red shift of the
Soret band at 428 nm. MPO is also the only member of the
mammalian peroxidase family that can e⁄ciently oxidize
chloride to hypochlorite. This peculiar enzymatic property
could be conferred by di¡erences in the amino acid environ-
ment of the heme, in particular by the presence of Met-409
linkage. All key residues, which constitute the active site wall,
on both the proximal and the distal side of the heme, are
strictly conserved in LPO, MPO and EPO, the only notewor-
thy di¡erence being indeed the Met-409 of MPO. Molecular
modeling clearly indicates that their location with respect to
the heme plan is conserved as well [13].
Previous studies using site-directed mutagenesis of MPO
revealed the nature of the bonds linking the heme group to
the amino acid backbone and showed the importance of Met-
409 for enzymatic activity [15^17] (Fig. 1).
One way to dissect the heme environment in mammalian
peroxidases consists of substituting amino acid residues in one
type of peroxidase by correspondingly located residues from
another type and to follow possible spectral and activity
changes. In this respect, the LPO/MPO pair is well suited
for these studies since these enzymes clearly di¡er in absorb-
ance spectrum and type of oxidized halides. Here we report
initial work along these lines wherein rLPO was ¢rst success-
fully obtained from engineered CHO cells and shown to dis-
play similar activity, spectroscopic and structural features as
those of the natural enzyme. In addition, a ¢rst amino acid
substitution, Gln-376/Met, was performed in an attempt to
confer MPO-like absorbance features and chlorinating activity
to rLPO. Failure to achieve the objective by a single mutation
underlines the complexity of interactions in the heme environ-
ment of mammalian peroxidases.
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2. Materials and methods
bLPO cDNA was ampli¢ed from mammary gland cells, using RT-
PCR with primers designed from the bLPO cDNA [8]. The length of
the ampli¢ed fragment covered the full length of bLPO (2295 bp). The
sequence analysis was performed in an Applied Biosystems sequencer.
The cDNA was introduced into the vector pcDNA3 (Invitrogen) as
an EcoRI-ApaI cassette, leading to the recombinant plasmid
pNIV2727. The mutant Gln-376/Met was constructed by the ligation
of a 250 bp BsmBI-MslI synthetic adaptor carrying the mutation,
leading to the recombinant plasmid pNIV2728. These plasmids were
transfected into COS cells, using the calcium phosphate coprecipita-
tion procedure [18], and into CHO cells DG44 dhfr3 [19] by electro-
permeabilization as described [20]. The cells were maintained in
KMEM+ supplemented with 5% fetal calf serum, 2 mM L-glutamine,
1% penicillin/streptomycin and selected for resistance to geneticin. The
production of rLPO was tested on the supernatant of the clones by
ELISA and by measurement of peroxidase activity using ABTS as
substrate [21]. After subcloning by limiting dilution, a large-scale
cell culture was carried out in a cell factory (Nunc), in the presence
of 3% fetal calf serum. The 3^4 day culture supernatants were centri-
fuged, passed over 0.22 Wm ¢lters and stored at 4‡C until puri¢cation.
The puri¢cation was performed on a Q-Sepharose fast-£ow column
and a CM-Sepharose fast-£ow column, equilibrated with 20 mM po-
tassium phosphate, pH 7.5 [20]. rLPO was eluted with a liner NaCl
gradient (0^450 mM) in the same bu¡er and collected in 10 ml frac-
tions. Natural bLPO, puri¢ed as described [22], was kindly given by
Dr. Nakamura, University of Hirosaki, and commercial bLPO was
obtained from Sigma. MPO-dependent chlorination activity was
measured at 25‡C by following the conversion of monochlorodimedon
to dichlorodimedon at 290 nm [23]. The covalent binding of heme to
rLPO was realized by preincubation of rLPO with 10 WM H2O2 as
described [24].
Monoclonal antibodies were prepared by fusion of the splenocytes
of immunized mice with myeloma cells (P3-X 63. Ag8U1: P3U1).
Several monoclonal antibodies were produced in BALB/c mice in-
jected intraperitoneally with the hybridoma cells. Ascitic £uids were
collected at 3^4 day intervals, ¢ltered through a 0.45 Wm ¢lter and the
monoclonal antibody, 1C3-2A, was employed at a 1/10 000 dilution
for immunoblotting and 1/7500 for ELISA. Western blots were per-
formed as described [20] and a direct ELISA procedure was devel-
oped, using anti-mouse alkaline phosphatase-labelled IgG and p-nitro-
phenylphosphate as substrate. Carbohydrate analysis was carried out
using the Glycan Di¡erentiation Kit (Boehringer), with the following
lectins: Galanthus nivalis agglutinin (GNA); Sambucus nigra aggluti-
nin (SNA) and Maackia amurensis agglutinin (MAA). N-Linked car-
bohydrates were removed by N-glycosidase F, high-mannose was re-
moved by endoglycosidase H and fully deglycosylated LPO was
prepared by digestion with N-glycosidase F, O-glycosidase and neu-
raminidase, following the manufacturer’s recommendations (Boeh-
ringer). N-terminal amino acid sequence was determined by auto-
mated Edman degradation with a Perkin Elmer 492 protein
sequencer. The positions of amino acid residues are identi¢ed by the
sequence alignments in the bovine preprolactoperoxidase and human
prepromyeloperoxidase [13].
3. Results and discussion
The sequence of the ampli¢ed bLPO cDNA presented three
di¡erences with respect to previously reported sequences [8].
However, there was no di¡erence in the deduced amino acid
sequence (Table 1). The recombinant plasmid pNIV2727 was
transfected into CHO dhfr3 cells and geneticin-resistant colo-
nies were selected. After selection and subcloning, one single
clone, 9E-3G, which presented the highest peroxidase activity
and reactivity in ELISA, was chosen for large-scale produc-
tion and puri¢cation. Since the isoelectric point of bLPO is
comparable to that of rMPO, the puri¢cation procedure pre-
viously used for rMPO was followed [20]. A total of 16 l of
spent culture medium was collected, leading after puri¢cation
to 13 mg of rLPO. After elution from the CM-Sepharose
column, the pooled fractions were analyzed on SDS-PAGE
and by Western blot, identifying two immunoreactive mole-
cules, a major 88 kDa and a minor 82 kDa species (Fig.
2A,B). The N-terminal amino acid sequences of these two
rLPO products were identical and started at residue Asp-101
(Fig. 3). While the cleavage of the propeptide in both 88 kDa
and 82 kDa molecules occurred between Arg-100 and Asp-
101, this was not the case for puri¢ed natural bLPO, nor for
commercial bLPO. These molecules were processed by cleav-
age of the Trp-119/Glu-120 and Thr-115/Ala-116 bonds, re-
spectively (Fig. 3). In fact, the N-terminal end of rLPO was
identical to that of the longest bLPO species sequenced by
Cals et al. [9]. This extended N-terminal end carries a putative
N-glycosylation site located at Asn-106.
The enzymatic activity of puri¢ed and concentrated rLPO
was then measured using ABTS as substrate; it was found to
display a lower speci¢c activity than that of the bLPO (184 U/
mg versus 337 U/mg). This di¡erence may be accounted for
by a lower heme content in the recombinant enzyme. rLPO in
its native state [Fe(III)] presents a major absorption peak at
413 nm (Soret peak), likewise bLPO (Table 2). The ratio (RZ)
of distinct absorptions at A413 and A280 was 0.54 for rLPO, as
compared to 0.88 for puri¢ed bLPO. This lower RZ could
re£ect, at least in part, a non-covalent state of the prosthetic
heme in rLPO, as was previously shown for the rLPO pro-
duced in insect cells [24]. To check this possibility we meas-
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Fig. 1. Heme environment in human MPO, from [17], showing the
three covalent bonds to residues Asp-260, Glu-408 and Met-409,
based on the 3D model of MPO [6,7].
Table 1
Summary of base changes for published sequences of bovine lactoperoxidase
Base pair position Present study Ref. [8] Ref. [25] Amino acid position and di¡erence
251 ATT ATC ATC Ile-43, no di¡erence
353 GCC GCA GCC Ala-77, no di¡erence
1598 CCA CCC CCC Pro-492, no di¡erence
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ured the increase in ABTS substrate oxidation by both rLPO
and bLPO pretreated with H2O2 as described previously [24].
The data showed a 40% increase in the activity of rLPO,
whereas there was no signi¢cant increase in that of bLPO
(Table 2). Apparently, pretreatment or the recombinant en-
zyme with H2O2 increased the covalent binding of the heme to
the apoprotein.
Carbohydrate analysis of rLPO and bLPO was performed
by sequential digestion of puri¢ed proteins using glycosidases,
followed by carbohydrate recognition with several speci¢c lec-
tins. After digestion with N-glycosidase F, the apparent mo-
lecular weight of bLPO (80 kDa) decreased to approximately
70 kDa (Fig. 2A,B). As seen in the same ¢gure, rLPO treated
with N-glycosidase F shifted in size from the major band of 88
kDa and the minor band of 82 kDa to 73 kDa and 69.5 kDa
species. From the shifts in apparent molecular mass, both
rLPO and bLPO appear to be N-glycosylated to roughly sim-
ilar extents (16% versus 12.5%). When treated with endogly-
cosidase H, bLPO displayed a signi¢cant mobility change; as
seen in Fig. 2A,B, bLPO lost about 8.0 kDa, whereas rLPO
decreased only 3 kDa in size. These shifts in apparent molec-
ular mass showed that the natural enzyme had a high man-
nose content of 9.8%, clearly higher than that of the recombi-
nant enzyme (3.4%). These results also indicated that the high
mannose content of natural bLPO reached 78%, whereas it
constituted only 20% of the total amount of N-glycans in the
recombinant enzyme.
Further experiments were performed to determine the pres-
ence of O-glycosylation in both species. To this end, digestion
of the molecules was achieved with N-glycosidase F, neurami-
nidase and O-glycosidase. As seen in Fig. 2A,B the size of the
rLPO and that of the bLPO did not change, indicating the
absence of O-linked sugars. Extents of digestion by glycosi-
dases and indications of the nature of the carbohydrate struc-
ture in bLPO and rLPO were studied using three lectins:
GNA, SNA and MAA (Table 3). rLPO and bLPO reacted
with GNA, pointing to the presence of terminal mannose
residues on both enzymes, either as high-mannose N-glycan
chains or as exposed mannose in hybrid chains. The enzymes
also reacted with MAA and SNA, revealing terminal N-ace-
tylneuraminic acid residues linked K(2-3) and K(2-6) to galac-
tose residues. All these observations were con¢rmed by the
concomitant disappearance of speci¢c lectin binding with
the extent of deglycosylation (Table 3).
In view of its overall identity with natural LPO, the re-
combinant species constitutes a suitable target for molecular
engineering. It was attempted to engineer rLPO in its heme
environment in order to modify spectral and activity charac-
teristics. The most obvious target was residue Gln-376, which
in view of its location appeared to correspond to Met-409 in
MPO [13]. Replacement in rLPO of Gln-376 by a methionine
residue was thus expected to confer the peculiar absorbance
spectrum and chlorinating activity, typical of MPO.
Recombinant plasmid pNIV2728 was therefore introduced
into COS cells and the secreted mutant carrying the Gln-376/
Met mutation was puri¢ed from supernatants of 8 day cell
culture. The puri¢ed mutant protein migrated on SDS-PAGE
as two immunoreactive bands having apparent masses identi-
cal as those observed for the wild-type rLPO (82 and 88 kDa).
The visible spectrum of the puri¢ed mutant was then com-
pared to that of the wild-type rLPO and revealed that the
absorption maximum remained at 413 nm, as in the wild-
type enzyme, instead of shifting to 428 nm as in MPO (Table
2).
The speci¢c peroxidase activity of the Met-376 mutant was
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Fig. 2. Carbohydrate analysis of rLPO and bLPO by SDS-PAGE and Western blot of puri¢ed LPOs untreated and digested with glycosidases.
Proteins were detected by silver staining (A) or by immunoblotting (B). Lane 1: bLPO untreated; lane 2: bLPO digested with endoglycosidase
H; lane 3: bLPO digested with N-glycosidase F; lane 4: bLPO digested with N-glycosidase F, neuraminidase and O-glycosidase; lane 5: rLPO
untreated; lane 6: rLPO digested with endoglycosidase H; lane 7: rLPO digested with N-glycosidase F; lane 8: rLPO digested with N-glycosi-
dase F, neuraminidase and O-glycosidase. Molecular mass standards are indicated by arrows.
Fig. 3. N-terminal amino acid sequences of puri¢ed 82 kDa and 88
kDa rLPO, of puri¢ed bLPO (1) and commercial bLPO (2). The se-
quence spans residues 101^125 of the bLPO amino acid sequence
deduced from the cDNA [8]. Underlined residues were identi¢ed by
automated Edman degradation. Parentheses show unidenti¢ed ami-
no acids.
Table 2











bLPO 413 337 0




Met-376 LPO 413 36 0
rMPO 428 69 59
Speci¢c peroxidase activity was measured using ABTS as substrate.
Visible spectra were recorded on a Cary 1E spectrophotometer.
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also measured, using ABTS as substrate, and the result
showed that the speci¢c activity was lower than for the
wild-type species (36.1 versus 184 U/mg). In addition, no
chlorinating activity could be detected for the mutant (Table
2). All these results show that the introduction of a methio-
nine instead of a glutamine in rLPO did not modify the spec-
trum of bLPO, suggesting that the covalent sulfonium linkage
of the heme with this methionine was not established in the
mutant rLPO.
The failure to engineer MPO-like properties into LPO by a
single mutation was disappointing inasmuch as the reverse
strategy used previously [15,17], i.e. substituting Met-409 in
MPO by Gln, led to the loss of the chlorinating activity, to a
red shift of the Soret peak from 428 nm to 413 nm and to the
relative decrease in peroxidase activity. Reasons for the failure
are not clear at this time but could be found in distortion of
the heme plan, which in MPO adopts a bow-like shape [7], or
to steric hindrances induced by the mutation. These con-
straints might have prevented the formation of a sulfonium
link with the methionine residue. Nevertheless, the availability
of rLPO and the approach here described open the way to a
detailed de¢nition of the heme environment in mammalian
peroxidases.
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Table 3
Carbohydrate analysis of natural and recombinant lactoperoxidase
Glycosidase treatment Binding of
GNA SNA MAA
Rec Nat Rec Nat Rec Nat
Untreated + + + + + +
Endo H 3 3 + + + +
N-Glyco F 3 3 3 3 3 3
N-Glyco F+O-glyco 3 3 3 3 3 3
bLPO and rLPO were treated with several glycosidases and the digested proteins were transferred onto nitrocellulose. Exposed carbohydrates were
detected with speci¢c lectins. GNA recognizes terminal mannose, K(1-3), K(1-6) or K(1-2) linked to mannose, thus it is suitable for identifying high-
mannose N-glycan chains; SNA recognizes sialic acid linked K(2-6) to galactose; MAA recognizes sialic acid linked K(2-3) to galactose. These
enzymes are thus suitable for identifying complex, sialylated carbohydrate N- or O-chains and the type of sialic acid linkage. + and 3 refer to
binding or not of the carbohydrate-speci¢c lectin.
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